Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Agenus Inc. before investing.

In this article, we go over a few key elements for understanding Agenus Inc.’s stock price such as:

• Agenus Inc.’s current stock price and volume
• Why Agenus Inc.’s stock price changed recently
• Upgrades and downgrades for AGEN from analysts
• AGEN’s stock price momentum as measured by its relative strength

About Agenus Inc. (AGEN)

Before we jump into Agenus Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Want to learn more about Agenus Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Agenus Inc..

Agenus Inc.’s Stock Price as of Market Close

As of May 21, 2026, 2:15 PM, CST, Agenus Inc.’s stock price was $3.185.

Agenus Inc. is up 1.11% from its previous closing price of $3.150.

During the last market session, Agenus Inc.’s stock traded between $3.080 and $3.200. Currently, there are approximately 37.94 million shares outstanding for Agenus Inc..

Agenus Inc.’s price-earnings (P/E) ratio is currently at 1.6, which is low compared to the Biotechnology industry median of 18.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Agenus Inc. Stock Price History

Agenus Inc.’s (AGEN) price is currently down 18.54% so far this month.

During the month of May, Agenus Inc.’s stock price has reached a high of $4.270 and a low of $3.020.

Over the last year, Agenus Inc. has hit prices as high as $7.340 and as low as $2.710. Year to date, Agenus Inc.’s stock is up 1.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Agenus Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there was 1 analyst who downgraded Agenus Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Agenus Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Agenus Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Agenus Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Agenus Inc. (AGEN) by visiting AAII Stock Evaluator.

Relative Price Strength of Agenus Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Agenus Inc. has a weighted four-quarter relative price strength of -7.91%, which translates to a Momentum Score of 34 and is considered to be Weak.

Want to learn more about how Agenus Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Agenus Inc. Stock Price: Bottom Line

As of May 21, 2026, Agenus Inc.’s stock price is $3.185, which is up 1.11% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Agenus Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.